# CJC-1295 Ipamorelin References: The Cited Literature

> CJC-1295 Ipamorelin references: the full cited literature behind every quantitative claim on this site — GH/IGF-1 pharmacodynamics, selectivity, GHRH-plus-GHRP synergy, DAC chemistry, and class safety.

Every load-bearing claim on this site, traced to its study.

## How these sources are used

Every quantitative claim on this site — each GH or IGF-1 fold-change, each duration, each selectivity result, each safety statement — maps to one of the numbered studies below. The pharmacodynamic and synergy literature is human or in-vivo where noted; the combination-specific claims do not exist, because no controlled human trial of the fixed CJC-1295/ipamorelin blend has been published, and this site does not invent one. Identifiers are given as DOI and PubMed links for verification.

## References

[1] Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[2] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. https://pubmed.ncbi.nlm.nih.gov/9849822/
[3] Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. https://pubmed.ncbi.nlm.nih.gov/2108187/
[4] Cunha SR, et al. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-82. https://pubmed.ncbi.nlm.nih.gov/12446584/
[5] Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. https://pubmed.ncbi.nlm.nih.gov/15817669/
[6] Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. https://pubmed.ncbi.nlm.nih.gov/28400207/
[7] Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. https://pubmed.ncbi.nlm.nih.gov/41545261/
[8] Weikel JC, et al. Ghrelin promotes slow-wave sleep in humans. Am J Physiol Endocrinol Metab. 2003;284(2):E407-15. https://pubmed.ncbi.nlm.nih.gov/12388174/
[9] Neuroendocrine circuit for sleep-dependent growth hormone release. Cell. 2025. https://pubmed.ncbi.nlm.nih.gov/40562026/
[10] Hoffman DM, et al. Short-term growth hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. J Clin Endocrinol Metab. 1996;81(3):1123-8. https://pubmed.ncbi.nlm.nih.gov/8772586/
[11] Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10. https://doi.org/10.5435/jaaosglobal-d-25-00236

---

A nightfall reading of the CJC-1295 and ipamorelin literature — the aurora is wonder, the steel is rigor, and nothing here is a clinic, a prescription, or a thing for sale.